|
22 Dec 2009 |
ABLYNX DEMONSTRATES PROOF-OF-CONCEPT BY BIOMARKER FOR ITS ANTI-THROMBOTIC ALX-0081
|
|
22 Dec 2009 |
Genentech Submits Supplemental Application to FDA for Lucentis in Patients with Retinal Vein Occlusion
|
|
22 Dec 2009 |
to-BBB and Lundbeck to join forces on brain delivery of antibodies for CNS diseases
|
|
21 Dec 2009 |
UCB announces initial clinical trial results involving patients taking certolizumab pegol for moderate to severe Crohn's disease
|
|
21 Dec 2009 |
Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with GlaxoSmithKline
|
|
18 Dec 2009 |
Amgen Receives CHMP Positive Opinion for Prolia(TM) (Denosumab) in the European Union
|
|
18 Dec 2009 |
Cangene receives a positive opinion from the European Medicines Agency ("EMA") for Hepatitis B product
|
|
18 Dec 2009 |
Thallion Announces Letter of Intent with LFB Biotechnologies to Develop and Commercialize Shigamabs®
|
|
18 Dec 2009 |
Herceptin receives positive opinion in record time for the treatment of HER2-positive advanced stomach cancer in Europe
|
|
17 Dec 2009 |
Adimab Announces New Antibody Discovery Collaborations and Achievement of Milestones in Two Existing Partnerships
|
|
16 Dec 2009 |
ABLYNX INITIATES PHASE I FOR ALX-0141 (ANTI-RANKL)
|
|
15 Dec 2009 |
Celldex Therapeutics Presents Positive Results from Phase 2 Study of the Antibody-Drug Conjugate (ADC) Product Candidate CDX-011 in Advanced Breast Cancer
|
|
15 Dec 2009 |
Seattle Genetics and Millennium: The Takeda Oncology Company Announce Strategic Collaboration for Novel Late Stage Lymphoma Program Brentuximab Vedotin (SGN-35)
|
|
14 Dec 2009 |
New Phase II Study Showed Trastuzumab-DM1 Shrank Tumors in Women With Highly Advanced HER2-positive Breast Cancer
|
|
11 Dec 2009 |
Seattle Genetics Announces Termination of Collaboration Agreement with Genentech for Dacetuzumab (SGN-40)
|
|
11 Dec 2009 |
Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
|
|
11 Dec 2009 |
Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
|
|
11 Dec 2009 |
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Woman Previously Treated with Chemotherapy for Advanced Breast Cancer
|
|
10 Dec 2009 |
Sanofi-aventis and U.S Biotechnology company Alopexx enter into a collaboration agreement for a novel human monoclonal antibody targeting infectious diseases
|
|
08 Dec 2009 |
Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
|
|
08 Dec 2009 |
SAR3419 Phase I Study Results in non-Hodgkin's Lymphoma at ASH
|
|
08 Dec 2009 |
Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting
|
|
08 Dec 2009 |
Novo Nordisk licenses IL-21 mAb and patent rights to IL-21 antibodies from ZymoGenetics
|
|
08 Dec 2009 |
Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia
|
|
08 Dec 2009 |
Immunomedics Reports Updated Results of Subcutaneous Humanized Anti-CD20 Antibody Therapy of Lymphoma With Veltuzumab
|
